Rusfertide vs Enlicitide: Hepcidin Mimetic and Oral PCSK9 Inhibitor Peptides Compared
Rusfertide mimics hepcidin for iron regulation in polycythemia vera; enlicitide is an oral PCSK9 inhibitor approved July 2026. Compares mechanisms, FDA status.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Rusfertide and enlicitide are two of 2026's most closely watched late-stage peptide therapeutics, yet they were engineered to solve almost opposite problems: one restores an iron-regulatory hormone the body already makes, the other reformulates a well-established cardiovascular drug class into a swallowable peptide. Rusfertide (PTG-300) is an injectable hepcidin-mimetic peptide advancing through FDA Priority Review for polycythemia vera, while enlicitide (marketed as Lipfendra) is an orally bioavailable macrocyclic peptide inhibitor of PCSK9 that received FDA approval in July 2026. Researchers tracking the "specialized research" peptide category increasingly compare the two not because they treat the same condition, but because they illustrate two very different engineering paths peptide drug developers are taking to reach commercial approval in the same calendar year.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Rusfertide and enlicitide are both late-stage 2026 peptide therapeutics but are not comparable for the same research application — rusfertide is a subcutaneous hepcidin-mimetic peptide in FDA Priority Review for polycythemia vera, while enlicitide is an orally dosed macrocyclic PCSK9 inhibitor already FDA-approved for LDL-cholesterol lowering, and researchers select between peptide modalities like these based on target pathway and evidence stage rather than head-to-head efficacy.
TL;DR:
- Rusfertide is a subcutaneous hepcidin mimetic (iron-regulation pathway); enlicitide is an oral macrocyclic peptide (PCSK9/LDL-receptor pathway).
- Rusfertide: FDA accepted Takeda's NDA with Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track designations; PDUFA goal date in Q3 2026.
- Enlicitide: FDA approved July 16, 2026, as Lipfendra, the first once-daily oral PCSK9 inhibitor.
- Both compounds illustrate a 2026 trend of macrocyclic and mimetic peptide engineering reaching late-stage or approved status outside the GLP-1 category.
- Neither compound is 503A-eligible for compounding; both are, or will be, branded specialty products only.
Rusfertide: Mechanism and Evidence Base
Rusfertide (PTG-300, TAK-121) is a synthetic peptide mimetic of hepcidin, the liver-derived hormone that governs systemic iron availability, developed by Protagonist Therapeutics in collaboration with Takeda. In polycythemia vera (PV), a chronic myeloproliferative neoplasm marked by excess red blood cell production, rusfertide binds ferroportin and blocks iron export from cells, restricting the iron supply available for erythropoiesis. That mechanism lowers hematocrit without the direct cytotoxic or myelosuppressive action of cytoreductive drugs such as hydroxyurea or interferon, positioning rusfertide as a mechanistically distinct alternative to therapeutic phlebotomy in PV research.
The evidence base has progressed through two randomized trials. In the Phase 2 REVIVE trial (New England Journal of Medicine, February 2024; PMID 38381675; NCT04057040), 60% of rusfertide-treated patients maintained hematocrit control without phlebotomy during the randomized-withdrawal phase, versus 17% on placebo (P=.002); mean maximum hematocrit fell from 50.0% pre-treatment to 44.5% on rusfertide. The Phase 3 VERIFY trial (NCT05210790, n=293) confirmed that signal at scale: rusfertide plus standard of care produced a 77% clinical response rate — defined as freedom from phlebotomy eligibility during weeks 20–32 — versus 33% for placebo plus standard of care, meeting its primary endpoint and all four key secondary endpoints. Four-year REVIVE/THRIVE extension data supporting long-term safety and durability was submitted as part of Takeda's New Drug Application, which the FDA accepted on March 2, 2026, with Priority Review and a PDUFA goal date in Q3 2026. Full trial and mechanism detail is cataloged on the rusfertide library profile.
Enlicitide: Mechanism and Evidence Base
Enlicitide (developmental code MK-0616, marketed as Lipfendra) takes a structurally unrelated approach. It is a highly engineered, orally bioavailable macrocyclic peptide inhibitor of PCSK9 (proprotein convertase subtilisin/kexin type 9), a liver protein that normally degrades LDL receptors and raises circulating LDL-cholesterol. Built as an octapeptide from two natural and six non-natural amino acids arranged into three fused macrocyclic rings, enlicitide resists gastrointestinal proteolysis while retaining high-affinity blockade of the PCSK9–LDL receptor interaction — an engineering feat historically limited to small molecules, since every prior FDA-approved PCSK9 inhibitor (evolocumab, alirocumab, inclisiran) requires subcutaneous injection.
Enlicitide's registrational evidence comes from the Phase 3 CORALreef program. In CORALreef Lipids (New England Journal of Medicine, February 2026; PMID 41879224; NCT05952856; n=2,904 adults with or at high risk for atherosclerotic cardiovascular disease), Phase 3 trials administered once-daily oral enlicitide 20 mg, which reduced LDL-cholesterol by 55.8% versus placebo at week 24, with concordant reductions in non-HDL-C, apolipoprotein B, and lipoprotein(a), and adverse event rates comparable to placebo. A parallel trial in heterozygous familial hypercholesterolemia (CORALreef HeFH, NCT05952869) showed a 59% placebo-adjusted LDL-C reduction. Based on that data package, the FDA approved enlicitide on July 16, 2026, as the first and only oral PCSK9 inhibitor. A large cardiovascular outcomes trial (CORALreef Outcomes, NCT06008756, more than 14,500 participants) is fully enrolled and ongoing to determine whether enlicitide reduces cardiovascular morbidity and mortality. Full profile data is available on the enlicitide library page.
Side-by-Side Comparison
| Rusfertide | Enlicitide | |
|---|---|---|
| Structural class | Linear hepcidin-mimetic peptide | Macrocyclic peptide (3 fused rings, 8 amino acids) |
| Target pathway | Ferroportin / iron export | PCSK9 / LDL receptor degradation |
| Route of administration | Subcutaneous injection | Oral, once-daily tablet |
| Primary research indication | Polycythemia vera (erythrocytosis control) | Hypercholesterolemia / ASCVD risk reduction |
| Regulatory status | Investigational — Priority Review, PDUFA Q3 2026 | FDA approved (Lipfendra), July 16, 2026 |
| Pivotal trial | Phase 3 VERIFY (NCT05210790) | Phase 3 CORALreef Lipids (NCT05952856) |
| 503A compounding status | Not eligible | Not eligible |
Differential Research Applications
Rusfertide and enlicitide do not compete for the same research question, so the comparison is instructive for a different reason: both illustrate how peptide chemists are solving the durability and bioavailability problems that have historically kept peptide therapeutics confined to injectable, short-course use. Rusfertide addresses durability by mimicking an endogenous regulatory hormone rather than introducing an entirely novel mechanism, which simplifies the safety story but still requires subcutaneous administration for a chronic, ongoing condition. Enlicitide takes the harder engineering path, using a macrocyclic, protease-resistant scaffold to achieve oral bioavailability for a target — PCSK9 — that had previously only been druggable via monoclonal antibody or siRNA injection. That same macrocyclic-engineering approach connects enlicitide to other recently approved oral peptides, including icotrokinra, an oral IL-23 receptor antagonist that reached FDA approval earlier in 2026 using a comparable protease-resistance strategy for an unrelated immunological target.
For researchers benchmarking where each compound's confirmatory and outcomes work currently stands — rusfertide's PDUFA timeline or enlicitide's ongoing CORALreef Outcomes trial — the clinical trial tracker aggregates trial status by phase and indication across the specialized-research peptide category, which is useful context given both compounds moved from pivotal data to regulatory decision within the same year.
Regulatory and Compounding Status
Neither compound is 503A-eligible for compounding-pharmacy preparation; both are, or will be, branded specialty pharmaceutical products. Rusfertide remains investigational: the FDA accepted Takeda's NDA with Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track designations, and a PDUFA goal date in Q3 2026, meaning a final approval decision was expected around the time this article was published. If approved, rusfertide would be dispensed as a branded injectable specialty drug. Enlicitide has already cleared that bar — Merck's Lipfendra received full FDA approval on July 16, 2026, as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, and is commercially available as a prescription-only oral tablet. Neither compound has a WADA Prohibited List determination relevant to its research use, since neither targets a performance-relevant pathway (erythropoiesis-adjacent iron regulation and lipid metabolism, respectively, sit outside WADA's growth hormone secretagogue and endocrine-modulator categories that govern most peptides on this site).
Cited Studies
- PMID 38381675 — "Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera." (New England Journal of Medicine, 2024). DOI: https://doi.org/10.1056/NEJMoa2308809
- PMID 41879224 — "A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide." (New England Journal of Medicine, 2026). DOI: https://doi.org/10.1056/NEJMoa2511002
Frequently asked questions
Q: Is rusfertide the same type of peptide as enlicitide?
A: No. Rusfertide is a linear peptide that mimics hepcidin, an endogenous iron-regulatory hormone, and is administered by subcutaneous injection. Enlicitide is a macrocyclic peptide engineered for oral bioavailability that inhibits PCSK9, an unrelated cholesterol-regulation target.
Q: Has rusfertide been approved by the FDA?
A: As of this article, rusfertide remains investigational. The FDA accepted Takeda's New Drug Application with Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track designations, and set a PDUFA goal date in Q3 2026.
Q: What is enlicitide approved for?
A: The FDA approved enlicitide (Lipfendra) on July 16, 2026, as an adjunct to diet and exercise to reduce LDL-cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, based on the Phase 3 CORALreef trial program.
Q: How is enlicitide different from other PCSK9 inhibitors?
A: Every previously approved PCSK9 inhibitor — evolocumab, alirocumab, and inclisiran — requires subcutaneous injection. Enlicitide is the first PCSK9 inhibitor formulated as a once-daily oral tablet, achieved through a protease-resistant macrocyclic peptide structure.
Q: Can rusfertide or enlicitide be obtained through compounding pharmacies?
A: No. Both are, or will be, FDA-regulated branded prescription products and are not eligible for 503A compounding-pharmacy preparation.
See also:
- Rusfertide Hepcidin Mimetic: Phase 3 VERIFY Trial Data and FDA Priority Review Status — a deeper standalone profile of rusfertide's mechanism and trial history.
- Next-Generation GLP-1 Peptides 2026: 9 Emerging Compounds Beyond Semaglutide and Tirzepatide — broader context on the 2026 late-stage peptide therapeutic pipeline.
- Icotrokinra vs Atacicept: Comparing Two Newly FDA-Approved Immunomodulatory Peptides — another comparison of two structurally distinct peptides that reached FDA approval within months of each other.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.